Silvia Marino
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Associate Staff Scientist
Also affiliated: Indiana University Health (2019–2020); Western General Hospital (2012–2020); Edinburgh Cancer Research (2012–2021); Moffitt Cancer Center (2025); Institute of Genetics and Cancer (2012–2021); Indiana University School of Medicine (2017–2023); Indiana University – Purdue University Indianapolis (2017–2025); University of Sheffield (2014–2021); University of Edinburgh (2012)
Staff Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Silvia Marino investigates therapeutic targets for multiple myeloma and related bone complications. Her work has identified Interleukin-33 (ILT3) as a target for immunotherapy and explored the role of cannabinoid receptors in cancer-induced bone pain. She has also studied pharmacological interventions, including targeting the p62 ZZ domain to enhance anti-tumor and bone-anabolic effects of bortezomib, and evaluating TRAF6/CD40 inhibitors for osteolysis. Marino's research has extended to developing novel therapeutic strategies, such as creating SEMA4A-directed CAR T cells to address low BCMA antigen density and generating bone-targeted inhibitors like BT-Amide for glucocorticoid-induced bone loss. Her scholarship metrics include an h-index of 17 across 48 publications with 741 citations.
Metrics
- h-index: 17
- Publications: 48
- Citations: 747
Selected Publications
-
DMP1-Cre expressing cells mediate the gain in bone mass and strength, but not the increase in bone remodeling, induced by ligands of the parathyroid hormone receptor (2026)
-
Loss of PTH 1 receptor signaling in periodontal cells drives cementum dysfunction and molar ankylosis in mice (2026)
-
2D and 3D In Vitro Co-culture for Cancer and Bone Cell Interaction Studies (2025)
-
Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss (2024)
-
Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation (2024)
Collaboration Network
Top Collaborators
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Loss of PTH 1 receptor signaling in periodontal cells drives cementum dysfunction and molar ankylosis in mice
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Loss of PTH 1 receptor signaling in periodontal cells drives cementum dysfunction and molar ankylosis in mice
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
- Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss
Similar Researchers
Based on overlapping research topics